MedPage Today on MSN

Practice-Influencing Results in Oligometastatic Prostate Cancer

Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...
News-Medical.Net on MSN

Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
UroToday

ASTRO 2025: 177Lu-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer: Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial

The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...
UroToday

ASTRO 2025: Patient-Reported Outcomes in a Randomized Trial of 18F-Fluciclovine vs. 68Ga-PSMA-11 PET/CT- Guided Post-Prostatectomy Radiation with Simultaneous Integrated Boosts

Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy radiotherapy. The study demonstrated an improvement in 3-year freedom from ...